Basilea Pharmaceutica (XSWX:BSLN) Other Stockholders Equity: CHF-3.9 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:BSLN Basilea Pharmaceutica Ltd XSWX:BSLN
61 GF Score
Price CHF53.10
GF Value CHF57.70
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Basilea Pharmaceutica Other Stockholders Equity?

Basilea Pharmaceutica XSWX:BSLN -2.93% 61 Other Stockholders Equity is CHF-3.9 Mil as of Dec. 2025. GuruFocus rates XSWX:BSLN with a GF Score™ of 61/100 and a GF Value™ of CHF57.70 (Fairly Valued). The stock has 4 warning signs investors should review.

Basilea Pharmaceutica's Other Stockholders Equity for the quarter that ended in Dec. 2025 was CHF-3.9 Mil.

Basilea Pharmaceutica's quarterly Other Stockholders Equity increased from Dec. 2024 (CHF-4.7 Mil) to Jun. 2025 (CHF-1.7 Mil) but then declined from Jun. 2025 (CHF-1.7 Mil) to Dec. 2025 (CHF-3.9 Mil).

Basilea Pharmaceutica's annual Other Stockholders Equity increased from Dec. 2023 (CHF-10.2 Mil) to Dec. 2024 (CHF-4.7 Mil) and increased from Dec. 2024 (CHF-4.7 Mil) to Dec. 2025 (CHF-3.9 Mil).

Basilea Pharmaceutica Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Basilea Pharmaceutica's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Basilea Pharmaceutica Other Stockholders Equity Chart

Basilea Pharmaceutica Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -21.62 -3.78 -10.21 -4.74 -3.90

Basilea Pharmaceutica Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.21 -9.00 -4.74 -1.67 -3.90
XSWX:BSLN
61GF Score
Basilea Pharmaceutica Ltd XSWX:BSLN
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Basilea Pharmaceutica Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of CHF-3.9 Mil mean?
Basilea Pharmaceutica (XSWX:BSLN) has a Other Stockholders Equity of CHF-3.9 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Basilea Pharmaceutica and its competitors.
Is Basilea Pharmaceutica's Other Stockholders Equity too high?
Basilea Pharmaceutica's current Other Stockholders Equity is CHF-3.9 Mil. Overall, Basilea Pharmaceutica has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Basilea Pharmaceutica's Other Stockholders Equity compare to VRTX and REGN?
Basilea Pharmaceutica's Other Stockholders Equity of CHF-3.9 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Basilea Pharmaceutica and its competitors. Basilea Pharmaceutica's current Other Stockholders Equity is CHF-3.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Basilea Pharmaceutica stock overvalued right now?
Based on GuruFocus' analysis, Basilea Pharmaceutica (XSWX:BSLN) is currently considered Fairly Valued. The stock's GF Value™ is CHF57.70, compared to a current price of CHF53.10 — trading 8% below its estimated fair value. The current Other Stockholders Equity is CHF-3.9 Mil. Basilea Pharmaceutica's overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Basilea Pharmaceutica (XSWX:BSLN), the current Other Stockholders Equity is CHF-3.9 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Basilea Pharmaceutica (XSWX:BSLN) Overvalued in 2026?

Based on GuruFocus' analysis, Basilea Pharmaceutica stock appears to be undervalued. The current stock price of CHF53.10 is trading 8% below its estimated GF Value™ of CHF57.70. GuruFocus considers Basilea Pharmaceutica to be Fairly Valued.

Key valuation signals for XSWX:BSLN:

  • Other Stockholders Equity: CHF-3.9 Mil
  • GF Value™: CHF57.70 vs. price of CHF53.10 (8% below fair value)
  • GF Score™: 61/100 with 4 warning signs

No single metric tells the full story. See the XSWX:BSLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Basilea Pharmaceutica Business Description

Address Hegenheimermattweg 167b, Allschwil, CHE, 4123
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.
61GF Score

Get the complete analysis for XSWX:BSLN

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF53.10
Price
CHF57.70
GF Value